Probiotics for Infectious Diarrhea in Children in South India

益生菌治疗印度南部儿童感染性腹泻

基本信息

  • 批准号:
    7599643
  • 负责人:
  • 金额:
    $ 8.05万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-04-01 至 2011-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The overall goal of this collaborative study submitted in response to PAR-07-216 (Indo- US Program for Maternal and Child Health) is to investigate whether the modulatory effects of probiotics in the gastrointestinal tract promote restoration of intestinal function and enhance the immune response in children with cryptosporidial or rotaviral infections in South India. Rotavirus and Cryptosporidium spp. are the most important viral and parasitic causes of gastroenteritis in children in south India. Both infections can lead to severe dehydrating gastroenteritis in young children as well as long term deleterious effects on nutritional status, likely due to intestinal damage. Most episodes of infectious gastroenteritis resolve with rehydration, but oral rehydration remains under-utilized, in part due to the lack of effect on frequency of bowel movements and duration of illness. Probiotics are known to beneficially modulate several host functions, the most important of which are immune responses and intestinal barrier integrity. Based on the established efficacy of Lactobacillus rhamnosus GG (LGG) for the treatment of a variety of diarrheal diseases and the documented modulation of immune responses and strengthening of intestinal epithelial barrier function by probiotics, we plan to conduct mechanistic studies on the effect of LGG vs. placebo in the resolution of symptoms and restoration of intestinal function, particularly permeability and carbohydrate absorption, in children with either rotaviral or cryptosporidial diarrhea and no other detected enteric infection. We will also study the effects of four weeks of supplementation with LGG on immune response to these infections. This study is a first step towards the goal of providing an understanding of a complementary therapy to treat acute diarrheal illness and its long term adverse consequences. LGG has the potential to be an easily accessible, cost effective approach to these pathogens of major public health importance. /Relevance Diarrhea causes significant death and disease in developing countries and the agents are usually acquired through food, water and poor hygiene. In these studies, we will study the effect of treatment of children with diarrhea due to the two most common pathogens in southern India, with probiotics or "good" bacteria in order to determine whether they help in preventing or repairing damage to the intestinal wall and whether they help in promoting an immune response that will protect from further infections. These studies are important to help understand whether and how probiotics work in protecting and healing the intestine.
描述(由申请人提供):这项针对 PAR-07-216(印美妇幼健康计划)提交的合作研究的总体目标是调查益生菌在胃肠道中的调节作用是否促进印度南部隐孢子虫或轮状病毒感染儿童肠道功能的恢复并增强免疫反应。轮状病毒和隐孢子虫属。是印度南部儿童胃肠炎最重要的病毒和寄生虫原因。这两种感染都可能导致幼儿严重脱水性胃肠炎,并可能由于肠道损伤而对营养状况产生长期有害影响。大多数感染性胃肠炎的发作可通过补液解决,但口服补液仍未得到充分利用,部分原因是口服补液对排便频率和疾病持续时间缺乏影响。众所周知,益生菌可以有益地调节多种宿主功能,其中最重要的是免疫反应和肠道屏障完整性。基于鼠李糖乳杆菌 GG (LGG) 治疗多种腹泻疾病的既定功效,以及益生菌对免疫反应的调节和增强肠上皮屏障功能的记录,我们计划对 LGG 与安慰剂相比在缓解症状和恢复肠道功能(特别是通透性和碳水化合物)方面的作用进行机制研究 患有轮状病毒或隐孢子虫腹泻且未检测到其他肠道感染的儿童的吸收。我们还将研究补充 LGG 4 周对这些感染的免疫反应的影响。这项研究是实现了解治疗急性腹泻疾病的补充疗法及其长期不良后果这一目标的第一步。 LGG 有潜力成为针对这些对公共卫生具有重要意义的病原体的一种易于获取且具有成本效益的方法。 /相关性 腹泻在发展中国家造成大量死亡和疾病,这些病原体通常通过食物、水和不良的卫生条件获得。在这些研究中,我们将研究用益生菌或“好”细菌治疗印度南部两种最常见病原体引起的儿童腹泻的效果,以确定它们是否有助于预防或修复肠壁损伤,以及是否有助于促进免疫反应,防止进一步感染。这些研究对于帮助了解益生菌是否以及如何发挥保护和治愈肠道的作用非常重要。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Honorine D Ward其他文献

Honorine D Ward的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Honorine D Ward', 18)}}的其他基金

Role of GAG-Binding Proteins in Cryptosporidium Infection
GAG 结合蛋白在隐孢子虫感染中的作用
  • 批准号:
    9203724
  • 财政年份:
    2016
  • 资助金额:
    $ 8.05万
  • 项目类别:
An Ex Vivo 3-D Pre-Clinical Human Enteroid Model for Cryptosporidium
隐孢子虫离体 3D 临床前人类肠样模型
  • 批准号:
    9090036
  • 财政年份:
    2015
  • 资助金额:
    $ 8.05万
  • 项目类别:
O-Glycan Synthesis: Potential Targets for Intervention in Cryptosporidiosis
O-聚糖合成:干预隐孢子虫病的潜在目标
  • 批准号:
    8410648
  • 财政年份:
    2012
  • 资助金额:
    $ 8.05万
  • 项目类别:
O-Glycan Synthesis: Potential Targets for Intervention in Cryptosporidiosis
O-聚糖合成:干预隐孢子虫病的潜在目标
  • 批准号:
    8496716
  • 财政年份:
    2012
  • 资助金额:
    $ 8.05万
  • 项目类别:
Immune Response to Cryptosporidiosis in a Birth Cohorot of Children of South Indi
南印度儿童出生队列对隐孢子虫病的免疫反应
  • 批准号:
    8072937
  • 财政年份:
    2010
  • 资助金额:
    $ 8.05万
  • 项目类别:
Immune Response to Cryptosporidiosis in a Birth Cohorot of Children of South Indi
南印度儿童出生队列对隐孢子虫病的免疫反应
  • 批准号:
    8111465
  • 财政年份:
    2010
  • 资助金额:
    $ 8.05万
  • 项目类别:
Immune Response to Cryptosporidiosis in a Birth Cohorot of Children of South Indi
南印度儿童出生队列对隐孢子虫病的免疫反应
  • 批准号:
    7911171
  • 财政年份:
    2009
  • 资助金额:
    $ 8.05万
  • 项目类别:
Role of Proteases in Cryptosporidium-Host Cell Interactions
蛋白酶在隐孢子虫-宿主细胞相互作用中的作用
  • 批准号:
    7878271
  • 财政年份:
    2009
  • 资助金额:
    $ 8.05万
  • 项目类别:
Immune Response to Cryptosporidiosis in a Birth Cohorot of Children of South Indi
南印度儿童出生队列对隐孢子虫病的免疫反应
  • 批准号:
    7687425
  • 财政年份:
    2008
  • 资助金额:
    $ 8.05万
  • 项目类别:
Immune Response to Cryptosporidiosis in a Birth Cohorot of Children of South Indi
南印度儿童出生队列对隐孢子虫病的免疫反应
  • 批准号:
    7907685
  • 财政年份:
    2008
  • 资助金额:
    $ 8.05万
  • 项目类别:

相似海外基金

Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10707830
  • 财政年份:
    2023
  • 资助金额:
    $ 8.05万
  • 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
  • 批准号:
    479728
  • 财政年份:
    2023
  • 资助金额:
    $ 8.05万
  • 项目类别:
    Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
  • 批准号:
    10884567
  • 财政年份:
    2023
  • 资助金额:
    $ 8.05万
  • 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
  • 批准号:
    10751964
  • 财政年份:
    2023
  • 资助金额:
    $ 8.05万
  • 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
  • 批准号:
    486321
  • 财政年份:
    2022
  • 资助金额:
    $ 8.05万
  • 项目类别:
    Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10676786
  • 财政年份:
    2022
  • 资助金额:
    $ 8.05万
  • 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10440970
  • 财政年份:
    2022
  • 资助金额:
    $ 8.05万
  • 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
  • 批准号:
    10642998
  • 财政年份:
    2022
  • 资助金额:
    $ 8.05万
  • 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10482465
  • 财政年份:
    2022
  • 资助金额:
    $ 8.05万
  • 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
  • 批准号:
    10191053
  • 财政年份:
    2020
  • 资助金额:
    $ 8.05万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了